Pure Global
NCT06277271

E-cigarettes as a Harm Reduction Strategy

E-cigarettes for Harm Reduction in Adults With Opioid Use Disorder
Prisma Health-Upstate·ClinicalTrials.gov·otherRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Smoking
Drug/Device/Intervention
E-cigarette
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Prisma Health-Upstate
Location
Greenville, United States of America
Timeline & enrollment
Phase
N/A
Start date
Jun 20, 2023
End date
Mar 20, 2024
Enrollment
30 participants
Primary outcome

Percentage of people who are eligible,Percentage of consented participants,Percentage of participants who report using the e-cigarette at least once a day,Percentage of participants with at least one puff of study e-cigarette,Percentage of daily diary completed

Summary

E-cigarettes have emerged as an effective strategy for replacing cigarettes among smokers
 from the general population, but there is a dearth of studies investigating their utility in
 replacing cigarettes among smokers with opioid use disorder (OUD). This study aims to
 evaluate the feasibility and acceptability of implementing a cigarette harm reduction
 intervention involving e-cigarettes in office-based buprenorphine clinics.

ICD-10 classifications
Tobacco useExposure to tobacco smokeToxic effect: Tobacco and nicotineMental and behavioural disorders due to use of tobacco : harmful useDrug use
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06277271
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06277271 through Pure Global AI's free database. This phase not specified trial is sponsored by Prisma Health-Upstate and is currently Recruiting. The study focuses on Smoking. Target enrollment is 30 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.